SCHEDULE: Invus Group Discloses 5.4% Stake in Neumora Therapeutics

Raymond Debbane and affiliated entities, collectively known as the Invus Group, have disclosed a beneficial ownership of 5.4% in Neumora Therapeutics, Inc.

Summary

• Raymond Debbane and a group of affiliated entities (Invus Public Equities, Invus Public Equities Advisors, Invus Global Management, Siren, Avicenna Life Sci Master Fund, Avicenna Life Sci Master GP, and Ulys) have filed a Schedule 13G.
• The group collectively beneficially owns 8,997,822 shares of Neumora Therapeutics, Inc. common stock.
• This aggregate ownership represents 5.4% of the company's outstanding common stock.
• The percentage is calculated based on 167,089,114 shares outstanding as of November 1, 2025, as reported by Neumora Therapeutics in its Form 10-Q.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, as it indicates a significant institutional investor group has taken a substantial stake in Neumora Therapeutics, which can be interpreted as a vote of confidence.

Positives

• A significant institutional investor group, led by Raymond Debbane, holds a substantial stake in Neumora Therapeutics, potentially signaling confidence in the company.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that institutional filings like Schedule 13G provide transparency into significant ownership positions, which can sometimes precede increased investor activism or strategic engagement, particularly in the biotechnology sector where capital allocation and pipeline development are critical.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and future strategic decisions.
• Management: Awareness of a substantial shareholder group that could engage in discussions regarding company strategy or governance.

Key Dates

Recommendation

The filing discloses a significant institutional ownership stake by Raymond Debbane and affiliated entities, representing 5.4% of Neumora Therapeutics. While this indicates a notable investor's position, the Schedule 13G itself does not provide operational or financial performance data to warrant a definitive buy or sell recommendation. A "hold" recommendation is appropriate as investors should monitor for further developments or subsequent filings that might elaborate on the investor group's intentions or the company's performance.

Keywords

Neumora Therapeutics, NMRA, Schedule 13G, Beneficial Ownership, Institutional Investor, Invus Public Equities, Raymond Debbane, Biotechnology, Pharmaceuticals, SEC Filing